Abstract
Erythropoietin-producing human hepatocellular receptor (EPH) B6 (EPHB6) is a member of the receptor tyrosine kinase family. We previously demonstrated that EPHB6 knockout reduces catecholamine secretion in male but not female mice, and castration reverses this phenotype. We showed here that male EPHB6 knockout adrenal gland chromaffin cells presented reduced acetylcholine-triggered Ca2+ influx. Such reduction depended on the non-genomic effect of testosterone. Increased large conductance calcium-activated potassium channel current densities were recorded in adrenal gland chromaffin cells from male EPHB6 knockout mice but not from castrated knockout or female knockout mice. Blocking of the large conductance calcium-activated potassium channel in adrenal gland chromaffin cells from male knockout mice corrected their reduced Ca2+ influx. We conclude that the absence of EPHB6 and the presence of testosterone would lead to augmented large conductance calcium-activated potassium channel currents, which limit voltage-gated calcium channel opening in adrenal gland chromaffin cells. Consequently, acetylcholine-triggered Ca2+ influx is reduced, leading to lower catecholamine release in adrenal gland chromaffin cells from male knockout mice. This explains the reduced resting-state blood catecholamine levels, and hence the blood pressure, in male but not female EPHB6 knock mice. These findings have certain clinical implications.
Similar content being viewed by others
Introduction
Erythropoietin-producing hepatocellular receptors (EPHs), the largest family of receptor tyrosine kinases, comprise about 25 percent of known receptor tyrosine kinases1. They are divided into A and B subfamilies (EPHAs and EPHBs), based on sequence homology. The EPHA subfamily has nine members, and EPHB has six members. Their ligand ephrins (EFNs) are also cell surface molecules1,2, which are also classified into A and B subfamilies (EFNAs and EFNBs) based on the way they anchor on the cell surface. EFNAs bind to the cell surface via glycosylphosphatidylinositol, while EFNBs are transmembrane proteins. The signaling from their ligand EFNs to EPHs is called forward signaling. EFNs, although ligands, can also transduce signals into cells2, and signaling from EPHs to EFNs is called reverse signaling. Interactions among EPHs and EFNs are promiscuous: a given EPH can interact with multiple EFNs and vice versa. In general, EPHA members bind preferentially to EFNA members, as EPHB members do to EFNB members2.
EPHs/EFNs function in many organs and systems2. Our laboratory was the first to report the critical roles of EPHs and EFNs in the immune system3,4,5,6,7,8,9,10,11,12,13,14,15. In the past five years, we have discovered novel functions of EPHs/EFNs in regulating blood pressure16,17,18,19,20,21. We reported that while EPHB6, EFNB1 and EFNB3 deletion results in blood pressure elevation, EPHB4 and EFNB2 deletion reduces it. Thus, EPHBs and EFNBs are a novel yin and yang system that finely tunes blood pressure homeostasis. In all such cases, sex hormones act in concert with these EPHs/EFNs for blood pressure regulation. We have established that vascular smooth muscle cells are target tissues for the blood pressure-regulating effect of these molecules. EPHB6, however, also targets cells responsible for catecholamine secretion. Male EPHB6 knockout (KO) mice have reduced blood catecholamine levels in a resting state16, which counteracts the outcome of increased vascular smooth muscle cell contractility, resulting in normal blood pressure. Castration of male KO mice leads to blood catecholamines returning to the normal level16. This, concomitantly with enhanced vascular smooth muscle cell contractility, results in blood pressure elevation in these castrated KO mice. This body of evidence indicates that EPHB6 and male sex hormones are acting in concert to regulate catecholamine secretion and blood pressure.
In the present study, we investigated the mechanism by which EPHB6 regulates adrenal gland chromaffin cell catecholamine secretion. We found that adrenal gland chromaffin cells from male KO mice were characterized by a reduced acetylcholine-dependent Ca2+ influx, involving non-genomic effects of testosterone. We further demonstrated that Ca2+ influx decrease was the consequence of enhanced large conductance calcium-activated potassium (BK) currents in these cells.
Materials and Methods
EPHB6 gene KO mice
EPHB6 KO mice were generated in our laboratory, as described previously7. They were backcrossed to the C57BL/6 background for more than 15 generations. Age- and sex-matched wild type (WT) littermates were used as controls. All experiments involving castrated mice were conducted at least three weeks post-operation.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
mRNA levels of EPHBS, EFNBS and BK channel subunits were measured by RT-qPCR. Total RNA from the adrenal glands, adrenal gland medullae and spleen was extracted with TRIzol® (Invitrogen, Burlington, Ontario, Canada) and reverse-transcribed with iScriptTMcDNA Synthesis Kit (Bio-Rad Laboratories (Canada) Ltd., Mississauga, Ontario, Canada). The primers used for PCR are listed in Supplementary Table 1. Conditions for the qPCR reactions were as follows: two minutes at 50 °C, two minutes at 95 °C, followed by 40 cycles of 10 seconds at 94 °C, 20 seconds at 58 °C, and 20 seconds at 72 °C. B-actin mRNA levels were considered as internal controls. qPCR signals between 22 and 30 cycles were analyzed. Samples were tested in triplicate, and the data were expressed as signal ratios of target RNA/β-actin mRNA.
Primary adrenal gland chromaffin cell culture
Mouse adrenal gland chromaffin cells were isolated, as described by Kolski-Andreaco et al.22, with modifications. Briefly, we obtained adrenal glands from 8- to 10-week-old mice, and fat and cortex were removed from these glands. Papain (P4762, Sigma-Aldrich, Oakville, Ontario, Canada) was activated with 5 mmol/L L-cysteine. Adrenal gland medullae were digested by activated papain in Hank’s buffer (2 medullae/100 μl Hank’s buffer containing four units of activated papain) at 37 °C for 25 min. They were washed twice with Hank’s buffer and then triturated by pipetting in 300 μl Hank’s buffer until they became feather-like. Cells were pelleted at 3,700 g for three minutes and re-suspended in Dulbecco’s modified Eagle’s medium (DMEM) containing 15% (v/v) fetal calf serum (FCS) for culture.
Epinephrine measurements
Adrenal glands were resected from EPHB6 KO and WT mice, and cut in half to expose the medulla. They were then stimulated with 5 mmol/L acetylcholine chloride (A2661, Sigma-Aldrich) in 300 μl Hank’s buffer at room temperature for one minute. Epinephrine levels in the supernatants were measured with Epinephrine Research ELISA kit (BAE-5100, Rocky Mountain Diagnostics, Colorado Springs, CO, USA), according to the manufacturer’s instructions. Samples were tested in duplicate by ELISA.
Immunofluorescence microscopy
Adrenal gland chromaffin cells were cultured in 6-well plates with cover glass placed at the bottom of the wells. After one day, the cells were washed once with phosphate-buffered saline (PBS) and fixed with 4% (w/v) paraformaldehyde for 20 minutes. They were then blocked with 10% (v/v) FCS in PBS for 20 minutes and incubated overnight at 4 °C with goat anti-mouse EPHB6 antibody (Ab; 2 µg/ml, R&D Systems, Minneapolis, MN, USA). They were then reacted with Alexa-488-conjugated donkey anti-goat Ab (2 µg/ml, Molecular Probes, Eugene, OR, USA) for two hours at room temperature, and imbedded with ProLong® Gold anti-fade reagent (Molecular Probes). Cell staining was examined with a Zeiss microscope.
Ca2+ influx measurements
Acetylcholine-stimulated Ca2+ influx in adrenal gland chromaffin cells was measured by microfluorescence technique23. Briefly, isolated adrenal gland chromaffin cells were incubated for 24 hours in DMEM containing 15% (v/v) FCS. The cells were loaded with Fura-2-AM (5 μmol/L) for 60 minutes at 37 °C. They were rinsed once in warm DMEM containing 15% (v/v) FCS without dye and placed in Hank’s balanced salt solution containing 1.26 mmol/L Ca2+ at 37 °C. They were stimulated with acetylcholine (5 mmol/L) at 37 °C and imaged for 120 seconds at a rate of approximately one measurement per two seconds for the two excitation wave lengths (the exposure time of a particular experiment varied slightly) with a Zeiss fluorescence microscope. Excitation wavelengths were recorded alternatively at 340 nm and 380 nm, and emission was registered at 510 nm. Signals from more than 15 randomly selected cells were recorded, and the results expressed as ratios of fluorescence intensity at 510 nm excited by 340 nm versus 380 nm.
Whole-cell patch clamping
Adrenal gland chromaffin cells were isolated and cultured for 24–48 hours. They were voltage-clamped to measure calcium and potassium current densities at 20–22 °C, with the perforated whole-cell (amphotericin B; 200μg/mL) configuration of the patch clamp technique as described in detail elsewhere24,25. For calcium current density monitoring, adrenal gland chromaffin cells were voltage-clamped at −70 mV, and 200-ms depolarizing pulses were applied at 5-mV steps from −50 to +45 mV, to construct I-V curves. For potassium current density measurement, adrenal gland chromaffin cells were voltage-clamped at −70 mV, and 750-ms depolarizing pulses were applied at 10-mV steps from −70 to +100 mV, in the absence or presence of paxilline, a BK channel blocker. Membrane currents were recorded and normalized to cell capacitance (I(pA/pF)) and current density-voltage curves were generated.
Ethics statement
All animal studies were approved by the Animal Protection Committee (Comité institutionnel d’intégration de la protection des animaux) of the CRCHUM. All experiments were conducted in accordance with relevant guidelines and regulations of the local government.
Statistical analysis
All results are presented as means ± S.E. The data were analyzed statistically by 2-tailed Student’s t-test, or a linear mixed-effect model (with genotype, individual cell, sex, sex hormone and time as qualitative factors). P-values of <0.05 are considered to be statistically significant.
Results
Reduced epinephrine secretion by adrenal glands from male but not female EPHB6 KO mice
We previously reported that male EPHB6 KO mice present decreased 24-hour urine catecholamine levels16. To establish causality of this phenotype to the adrenal glands, we measured the KO adrenal gland catecholamine secretion by RT-PCR. As anticipated, RT-qPCR showed that the adrenal gland from KO mice did not express EPHB6 at the mRNA level (Fig. 1A). No compensatory mRNA up-regulation of other EPHB members, such as EPHB1, EPHB2, EPHB3 or EPHB4, was evident in adrenal glands (Supplementary Figure 1 (S. Figure 1) from male, female or castrated KO mice. Nor was there abnormal expression of mRNA levels of EPHB6 ligands (EFNB1, EFNB2 and EFNB3) in these KO adrenal gland chromaffin cells (S. Figure 2). EPHB6 protein expression was undetectable by immunofluorescence in KO adrenal gland chromaffin cells (Fig. 1B). KO adrenal glands were of similar size as WT counterparts and showed no histological abnormalities (Fig. 1C). No significant difference in the size of adrenal gland chromaffin cells isolated from KO versus WT adrenal glands was observed (Fig. 1D). Acetylcholine-stimulated catecholamine secretion by KO adrenal glands was then assessed with epinephrine as a representative catecholamine. Adrenal glands from male but not female KO mice presented reduced epinephrine secretion, but castration reversed this KO phenotype by augmenting epinephrine secretion to normal levels (Fig. 1E). This observation is consistent with catecholamine levels in the in vivo KO mice, and supports the hypothesis that EPHB6 and male sex hormones jointly regulate catecholamine secretion from adrenal gland chromaffin cells.
EPHB6 and testosterone jointly regulate adrenal gland chromaffin cell Ca2+ influx
Ca2+ influx is the main trigger for catecholamine release in adrenal gland chromaffin cells. Defective catecholamine release in adrenal gland chromaffin cells from male KO mice prompted the examination of Ca2+ influx in these cells. Acetylcholine-stimulated Ca2+ influx was significantly reduced in adrenal gland chromaffin cells from male but not female KO mice (Fig. 2A), corroborating the catecholamine phenotype in vivo. Castration rescued Ca2+ influx in KO adrenal gland chromaffin cells to a level similar to that of their WT counterparts, while it had no impact on that of adrenal gland chromaffin cells from WT males (Fig. 2B). To disentangle the effects between sex hormones and sex, we treated adrenal gland chromaffin cells from castrated males with testosterone. While Ca2+ influx in adrenal gland chromaffin cells from castrated WT mice was not affected by 15-minute testosterone treatment, it was augmented in adrenal gland chromaffin cells from castrated KO mice to the level of their WT counterparts (Fig. 3A), indicating that testosterone rather than sex influenced Ca2+ influx. The rapid response of adrenal gland chromaffin cells to testosterone treatment (15 minutes) also suggests that the effect is non-genomic. To confirm this finding, adrenal gland chromaffin cells were treated with bovine serum albumin (BSA)-conjugated testosterone, which cannot penetrate the cell membrane and can only exert non-genomic effects. Again, similarly to regular testosterone, 15-minute treatment with this membrane-impermeable testosterone augmented Ca2+ influx in adrenal gland chromaffin cells from castrated KO mice, but not in adrenal gland chromaffin cells from castrated WT mice (Fig. 3B), indicating that the effect is indeed non-genomic.
Based on these findings, testosterone-induced Ca2+ influx suppression in the absence of EPHB6 is expected in adrenal gland chromaffin cells from female KO mice. Indeed, 15-minute testosterone treatment reduced Ca2+ influx in adrenal gland chromaffin cells from female KO but not in WT mice (Fig. 3C). Moreover, BSA-conjugated cell membrane-impermeable testosterone was equally effective in these adrenal gland chromaffin cells from female KO mice (Fig. 3D), supporting non-genomic effects of the testosterone on adrenal gland chromaffin cells Ca2+ influx.
The lack of estrogen as a potential cause for the observed reduced Ca2+ influx in adrenal gland chromaffin cells from male KO mice was then explored. Adrenal gland chromaffin cells from male KO mice were exposed to estrogen for 15 minutes (Fig. 3E) or 24 hours (Fig. 3F). Regardless of the exposure time, estrogen had no effect on adrenal gland chromaffin cells from male KO or WT mice in terms of acetylcholine-stimulated Ca2+ influx. This strongly suggests that testosterone alone, but not estrogen, in concert with EPHB6, regulates adrenal gland chromaffin cell Ca2+ influx.
Effects of EPHB6 and male sex hormone on adrenal gland chromaffin cell electrophysiological properties
Voltage-gated calcium channel function in adrenal gland chromaffin cells from KO mice was electrophysiologically assessed using the perforated patch clamp technique (Fig. 4). According to the calcium influx data, smaller calcium current densities were expected. Unexpectedly, calcium current densities were significantly higher in male KO adrenal gland chromaffin cells (Fig. 4A). Whilst castration increased Ca2+ current densities in WT adrenal gland chromaffin cells (Fig. 4B), no significant changes were observed in male KO adrenal gland chromaffin cells (Fig. 4C). As a consequence, castration abolished the difference in calcium current-voltage relationships between WT and KO adrenal gland chromaffin cells (Fig. 4D). It should be noted that although the deletion of EPHB6 and the presence of testosterone could potentially increase voltage-gated calcium channels current densities during patch clamping, such increase might not happen in an intact cell under a physiological condition (otherwise, the Ca2+ influx would have increased in male KO adrenal gland chromaffin cells), and hence the alternation of voltage-gated calcium channel function is not the direct cause for the EPHB6-associated decrease in Ca2+ influx of male KO adrenal gland chromaffin cells.
Indirect modulation of voltage-gated calcium channels activity, and subsequent calcium influx, can occur through the regulation of membrane potential. Opening of BK channels strongly hyperpolarizes cell membrane and thus leads to the closure of voltage-gated calcium channels in adrenal gland chromaffin cells. The impact of EPHB6 and testosterone on BK channel function was investigated. Outward K+ currents were significantly larger in adrenal gland chromaffin cells from male KO mice compared to their WT counterparts (Fig. 5A). Paxilline, a BK channel blocker, almost completely abolished the currents in both groups (Fig. 5B). This indicates that the outward K+ currents in WT and KO adrenal gland chromaffin cells occur mainly via BK channels. The paxilline-sensitive BK channel currents were significantly higher in male KO adrenal gland chromaffin cells than that in WT adrenal gland chromaffin cells (Fig. 5C), and castration significantly decreased BK currents in KO but not WT adrenal gland chromaffin cells (Fig. 5D and E). Therefore, BK currents became similar in WT and KO adrenal gland chromaffin cells after castration (Fig. 5F).
We identified BK function as a critical link in response to testosterone with regard to Ca2+ influx in the EPHB6 KO adrenal gland chromaffin cells. In vitro (or rather, ex vivo), the Ca2+ current density of adrenal gland chromaffin cells of the KO mice was rapidly augmented within 15 minutes by testosterone, suggesting non-genomic effect of the androgen. However, this cannot exclude the possibility that in vivo, testosterone and EPHB6 also affect BK channel expression through genomic effects via classical nuclear androgen receptors26, which would increase BK current densities in vivo or ex vivo. Besides, in vivo, the longer time frame will allow the rapid non-genomic signaling of testosterone via Src kinases27 or cell surface androgen receptors28 to travel to the nuclei, converting non-genomic effects to genomic effects. Therefore, it is necessary to evaluate the BK expression ex vivo from WT and KO chromaffin cells. BK channels are composed of four pore-forming alpha subunits and a regulatory beta-subunit isoform29. We probed for their expression in mouse adrenal gland chromaffin cells, and found that the beta 2 subunit (KCNMB2) was the dominant beta subunit isoform in these cells (S. Figure 3). However, no difference in the expression of either the alpha or beta subunit mRNA was detected in adrenal gland chromaffin cells from KO males WT in males or from castrated KO and WT males. This suggests that the regulation of BK channels by EPHB6 and testosterone do not occur at the expression level.
Our data indicate that enhanced BK currents in male KO adrenal gland chromaffin cells might lead to decreased open probability of voltage-gated calcium channels, reducing Ca2+ influx in these cells. If so, blocking BK channels would prevent voltage-gated calcium channel inhibition and increase Ca2+ influx in male KO adrenal gland chromaffin cells. To test this hypothesis, adrenal gland chromaffin cells were treated with a BK channel inhibitor, penitrem A. Ca2+ influx was unaltered by penitrem A in male WT adrenal gland chromaffin cells (Fig. 6A), but it was significantly increased in KO adrenal gland chromaffin cells, reverting to WT control levels (Fig. 6B).
Discussion
The present study revealed that EPHB6 deletion decreased male but not female adrenal gland chromaffin cell Ca2+ influx and catecholamine secretion. Testosterone was required for this phenotype, as the absence of both EPHB6 and testosterone reversed the KO adrenal gland chromaffin cell phenotype to that of their WT controls. The functional mechanism involves BK channels.
Ca2+ influx is an essential signal triggering catecholamine release from adrenal gland chromaffin cells. Our data shows that this Ca2+ influx is compromised in male EPHB6 KO adrenal gland chromaffin cells. The electrophysiology of adrenal gland chromaffin cells related to Ca2+ influx is depicted in Fig. 7. In adrenal gland chromaffin cells, acetylcholine stimulation of acetylcholine receptors evokes a small Ca2+ influx plus a large Na+ influx. The combined effect of these inward cations causes depolarization, which increases voltage-gated calcium channels open probability and leads to a larger Ca2+ influx30. Ensuing BK channel activation re-hyperpolarizes adrenal gland chromaffin cell membrane31. This re-hyperpolarization reduces voltage-gated calcium channels’ opening and thus terminates Ca2+ influx32. The decreased calcium influx and catecholamine release observed in male EPHB6 KO mice could have resulted from a decrease in calcium channels’ function. However, perforated patch recordings show voltage-gated calcium channels’ current densities were rather larger in adrenal gland chromaffin cells from KO compared to that of their WT littermates. These results strongly suggest that EPHB6 modulation of calcium influx is not due to direct suppression of voltage-gated calcium channel function.
Alternatively, EPHB6’s control of Ca2+ influx could be indirect through stabilizing (or repolarizing) the membrane potential of adrenal gland chromaffin cells. Given the high input resistance of adrenal gland chromaffin cells, a small modification of membrane conductance would be sufficient to abolish or substantially limit membrane depolarization. K+ currents thus play a major role in controlling membrane potential of adrenal gland chromaffin cells and catecholamine release. Indeed, K+ currents appear to be modified in male KO adrenal gland chromaffin cells. BK channels were the main K+ conductance altered by EPHB6 expression, as their current densities were in accordance with the adrenal gland chromaffin cell phenotype observed. In male KO adrenal gland chromaffin cells, BK current densities were substantially increased (Fig. 5C), and castration abolished such increase (Fig. 5D and F). We thus propose the model illustrated in Fig. 7 to portray the mechanism by which EPHB6 and testosterone act in concert to modulate adrenal gland chromaffin cell Ca2+ influx. Testosterone enhances BK currents either through direct binding with the ion channel33, by non-genomic signaling through Src kinases27 or its cell surface androgen receptors28. On the other hand, EPHB6 might interfere with the testosterone-BK channel, testosterone-androgen receptor, or testosterone-Src interactions (to be confirmed, and hence marked with question marks). As a consequence, the presence of EPHB6 suppresses the positive effect of testosterone on BK channel activity. Abolished expression of EPHB6 in KO mice alleviates the inhibitory influence of testosterone over BK channels, leading to a larger K+ efflux. This evokes an earlier and faster repolarization, decreases sustained voltage-gated calcium channels’ probability to open, and subsequently reduces Ca2+ influx.
This proposed model (Fig. 7) is validated by our experimental data. Indeed, a BK channel blocker, penitrem A, effectively augmented Ca2+ influx in male KO adrenal gland chromaffin cells, corroborating the critical role of BK channel activity in decreasing Ca2+ influx in these cells. The current literature also supports our model. Testosterone has been shown to increase the BK current34. A recent report indicated that testosterone can interact directly with BK channel subunits in rat anterior pituitary tumor cells and modulate their function in patch-clamp assays33. Therefore, direct testosterone binding to BK channels in adrenal gland chromaffin cells might enhance BK channel activity. BK channel function would not be altered in male WT adrenal gland chromaffin cells by testosterone, because EPHB6 blocks BK channel’s association with the latter. BK currents are not altered in female KO adrenal gland chromaffin cells either, despite the absence of EPHB6, because of low testosterone levels. Moreover, BK channel currents are normal in female WT adrenal gland chromaffin cells, due to both the absence of testosterone and the presence of EPHB6. To test these hypotheses, we conducted immunoprecipitation and fluorescence resonance energy transfer to assess physical interactions between EPHB6 and KCNMB2, the major regulatory β subunit, but to no avail (data not shown). Limitations of the approaches, such as assay sensitivity and affinity between EPHB6 and BK β-subunit, could account for such negative results. Further investigation in this regard would thus be required.
Androgens have two major forms: testosterone and 5α-dihydrotestosterone. The latter is a metabolite of the former, and binds with higher affinity to androgen receptors35. Classical androgen receptors are intracellular proteins, and upon binding to testosterone or 5α-dihydrotestosterone, they translocate into nuclei and serve as DNA-binding transcription factors that regulate genes with androgen-responsive elements36. This is called genomic action. Androgen receptors can also interact directly with Src kinases and trigger their activation27. Cell membrane androgen receptors exist too, and they may be G protein–associated but are poorly characterized28,37,38,39. The latter two actions are non-genomic.
Our study in vitro reveals that the non-genomic effect of testosterone appears to be sufficient to cause increased Ca2+ influx in male KO adrenal gland chromaffin cells. It is likely that this observed androgen effect is not unique for testosterone; other testosterone derivatives, such as the more potent 5α-dihydrotestosterone, might also be effective. This will need to be confirmed. Such in vitro non-genomic effect does not exclude the existence of possible in vivo genomic effect of androgens, as they are not mutually exclusive. The possible in vivo genomic effect of androgen on Ca2+ influx could be confirmed or refuted by using mice with adrenal gland-specific null mutation of the classical intracellular androgen receptor. To the best of our knowledge, such a study has not been conducted and would be interesting to perform.
It is conceivable that males with EPHB6 loss-of-function mutations might become hypertensive later in life because of decreased testosterone levels, which may cause them to lose the blood pressure-lowering beneficial effect of EPHB6 mutation by increasing their resting-state catecholamine levels. Consequently, their blood pressure might increase due to other genetic and environmental factors, as hypertension is a polygenic and multifactorial disease. For these patients, testosterone replacement therapy might restore the protective influence of EPHB6 mutation in lowering catecholamine secretion and hence, blood pressure.
The effect of testosterone on blood pressure is often controversial. In animal studies, castration often results in lower blood pressure40,41,42. In humans, different studies reported mixed results, probably due to the heterogeneity of the human population. Male hypogonadism is known to associate with hypertension43,44,45,46,47,48. There are multiple articles showing blood pressure reduction after testosterone replacement therapy49,50,51,52. These and additional favorable results with regard to testosterone replacement therapy in reducing cardiovascular risks including blood pressure are discussed in two recent review papers53,54. It is true that a couple of large retrospective studies have revealed that testosterone replacement therapy is associated with increased cardiovascular risks55,56. However, the conclusions from these studies are disputed as “retrospective, highly statistical and only with a minor effect size” and “are unlikely reproducible or accurate”54. It is safe to say that the effects of testosterone replacement therapy on cardiovascular risks are not conclusive.
The results of clinical studies are rarely black and white (i.e., with 100% penetrance). Rather, the conclusions depend heavily on statistical analysis, which has the limitation of discounting the responses of a subpopulation within the case group. For example, in a drug efficacy study, if we assume a placebo effect occurs in 20% of a control group, and a positive therapeutic effect of 35% in a drug-treated group, which represents a very moderate efficacy, we will only need 138 individuals each in the control and treated group to achieve 80% power to arrive at a conclusion that the treatment is statistically effective. In this case, the fate of 65% of treated but non-responsive patients is practically ignored. In a real example of using diuretics in treating acute congestive heart failure, more than 50% of the treated patients are not responding to 40 mg/furosemide in terms of body weight reduction57, and yet furosemide is still used to treat this condition. For the same reason but in a reverse way, the statistically significant side-effect of testosterone replacement therapy does not mean that the side-effect occurs in all the individuals. It is totally possible that for a subpopulation of hypogonadic patients with EPHB6 loss-of-function mutations, testosterone replacement therapy does not cause increased cardiovascular risks, but reduces resting state catecholamine secretion, and hence their blood pressure. For these individuals, testosterone might be a causative rather than symptomatic treatment for their hypertension. After all, testosterone administered in a proper dosage and format will restore what they used to have in sufficient quantity in their adult life.
The potential risk of testosterone in promoting prostate cancer is a concern. However, this is mitigated because patients with prostate cancer or elevated prostates-specific antigen levels are routinely excluded from testosterone replacement therapy. Also, multiple short- and long-term (five years) testosterone replacement therapy studies have found no evidence of prostate-specific antigen level increases49,52,58, further alleviating the concern.
The current anti-hypertensive drugs are highly effective with minimal side-effects. This has made the entry threshold of testosterone as a new therapeutic agent much higher. However, in the age of personalized medicine, for those whose hypertension is caused by EPHB6 mutations and subsequent hypogonadism, if testosterone could address the cause rather than symptoms, its therapeutic application should be considered.
The present study reveals a novel mechanism by which EPHB6 and testosterone jointly regulate catecholamine release from adrenal gland chromaffin cells. The results might explain some controversial findings with regard to cardiovascular benefits or risks after testosterone replacement therapy. Further, this study has raised a possibility of using testosterone as a personalized medicine to lower resting-state catecholamine secretion and hence, blood pressure.
References
Committee, E. N. Unified nomenclature for Eph family receptors and their ligands, the ephrins. Cell 90, 403–404 (1997).
Pasquale, E. B. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133, 38–52 (2008).
Luo, H., Wan, X., Wu, Y. & Wu, J. Cross-linking of EphB6 resulting in signal transduction and apoptosis in Jurkat cells. The Journal of Immunology 167, 1362–1370 (2001).
Luo, H., Yu, G., Wu, Y. & Wu, J. EphB6 crosslinking results in costimulation of T cells. The Journal of clinical investigation 110, 1141–1150 (2002).
Yu, G., Luo, H., Wu, Y. & Wu, J. Ephrin B2 induces T cell costimulation. The Journal of Immunology 171, 106–114 (2003).
Yu, G., Luo, H., Wu, Y. & Wu, J. Mouse ephrinB3 augments T-cell signaling and responses to T-cell receptor ligation. Journal of Biological Chemistry 278, 47209–47216 (2003).
Luo, H., Yu, G., Tremblay, J. & Wu, J. EphB6-null mutation results in compromised T cell function. The Journal of clinical investigation 114, 1762–1773 (2004).
Yu, G., Luo, H., Wu, Y. & Wu, J. EphrinB1 is essential in T-cell-T-cell co-operation during T-cell activation. Journal of Biological Chemistry 279, 55531–55539 (2004).
Wu, J. & Luo, H. Recent advances on T-cell regulation by receptor tyrosine kinases. Current opinion in hematology 12, 292–297 (2005).
Yu, G., Mao, J., Wu, Y., Luo, H. & Wu, J. Ephrin-B1 is critical in T-cell development. Journal of Biological Chemistry 281, 10222–10229 (2006).
Luo, H. et al. Efnb1 and Efnb2 proteins regulate thymocyte development, peripheral T cell differentiation, and antiviral immune responses and are essential for interleukin-6 (IL-6) signaling. Journal of Biological Chemistry 286, 41135–41152 (2011).
Luo, H. et al. EFNB1 and EFNB2 physically bind to IL-7R-alpha and retard its internalization from the cell surface (57.2). The Journal of Immunology 186, 57.52–57.52 (2011).
Jin, W., Luo, H. & Wu, J. Effect of reduced EPHB4 expression in thymic epithelial cells on thymocyte development and peripheral T cell function. Molecular immunology 58, 1–9 (2014).
Hu, Y. et al. Role of EFNB1 and EFNB2 in Mouse Collagen‐Induced Arthritis and Human Rheumatoid Arthritis. Arthritis & Rheumatology 67, 1778–1788 (2015).
Luo, H. et al. EphrinB1 and EphrinB2 regulate T cell chemotaxis and migration in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurobiology of disease 91, 292–306 (2016).
Luo, H. et al. Receptor tyrosine kinase Ephb6 regulates vascular smooth muscle contractility and modulates blood pressure in concert with sex hormones. Journal of Biological Chemistry 287, 6819–6829 (2012).
Wu, Z. et al. Possible role of Efnb1 protein, a ligand of Eph receptor tyrosine kinases, in modulating blood pressure. Journal of Biological Chemistry 287, 15557–15569 (2012).
Wang, Y. et al. EPHB4 protein expression in vascular smooth muscle cells regulates their contractility, and EPHB4 deletion leads to hypotension in mice. Journal of Biological Chemistry 290, 14235–14244 (2015).
Wang, Y. et al. Reduced blood pressure after smooth muscle EFNB2 deletion and the potential association of EFNB2 mutation with human hypertension risk. European Journal of Human Genetics (2016).
Wang, Y. et al. Estrogen and testosterone in concert with EFNB3 regulate vascular smooth muscle cell contractility and blood pressure. American Journal of Physiology-Heart and Circulatory Physiology 310, H861–H872 (2016).
Wang, Y. et al. The role of GRIP1 and ephrin B3 in blood pressure control and vascular smooth muscle cell contractility. Sci Rep 6, 38976, https://doi.org/10.1038/srep38976 (2016).
Kolski-Andreaco, A., Cai, H., Currle, D. S., Chandy, K. G. & Chow, R. H. Mouse adrenal chromaffin cell isolation. J Vis Exp, 129, https://doi.org/10.3791/129 (2007).
Grynkiewicz, G., Poenie, M. & Tsien, R. Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260, 3440–3450 (1985).
Ledoux, J., Bonev, A. D. & Nelson, M. T. Ca2+ -activated K+ channels in murine endothelial cells: block by intracellular calcium and magnesium. The Journal of general physiology 131, 125–135 (2008).
Ledoux, J., Greenwood, I., Villeneuve, L. R. & Leblanc, N. Modulation of Ca2+ ‐dependent Cl− channels by calcineurin in rabbit coronary arterial myocytes. The Journal of physiology 552, 701–714 (2003).
Lubahn, D. B. et al. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 2, 1265–1275, https://doi.org/10.1210/mend-2-12-1265 (1988).
Yu, J. et al. Src kinase-mediates androgen receptor-dependent non-genomic activation of signaling cascade leading to endothelial nitric oxide synthase. Biochem Biophys Res Commun 424, 538–543, https://doi.org/10.1016/j.bbrc.2012.06.151 (2012).
Thomas, P., Converse, A. & Berg, H. A. ZIP9, a novel membrane androgen receptor and zinc transporter protein. Gen Comp Endocrinol, https://doi.org/10.1016/j.ygcen.2017.04.016 (2017).
Yuan, P., Leonetti, M. D., Pico, A. R., Hsiung, Y. & MacKinnon, R. Structure of the human BK channel Ca2+ -activation apparatus at 3.0 A resolution. Science 329, 182–186, https://doi.org/10.1126/science.1190414 (2010).
Fenwick, E. M., Marty, A. & Neher, E. Sodium and calcium channels in bovine chromaffin cells. J Physiol 331, 599–635 (1982).
Martinez-Espinosa, P. L., Yang, C., Gonzalez-Perez, V., Xia, X. M. & Lingle, C. J. Knockout of the BK beta2 subunit abolishes inactivation of BK currents in mouse adrenal chromaffin cells and results in slow-wave burst activity. J Gen Physiol 144, 275–295, https://doi.org/10.1085/jgp.201411253 (2014).
Solaro, C. R., Prakriya, M., Ding, J. P. & Lingle, C. J. Inactivating and noninactivating Ca(2+)- and voltage-dependent K+ current in rat adrenal chromaffin cells. J Neurosci 15, 6110–6123 (1995).
Suárez, L., Bilal, U., Bordallo, J., Cantabrana, B. & Sánchez, M. Androgens block outward potassium currents and decrease spontaneous action potentials in GH3 cells. Naunyn-Schmiedeberg’s archives of pharmacology 388, 67–78 (2015).
Han, D. H. et al. Effect of testosterone on potassium channel opening in human corporal smooth muscle cells. The journal of sexual medicine 5, 822–832 (2008).
Toth, M. & Zakar, T. Relative binding affinities of testosterone, 19-nortestosterone and their 5 alpha-reduced derivatives to the androgen receptor and to other androgen-binding proteins: a suggested role of 5 alpha-reductive steroid metabolism in the dissociation of “myotropic” and “androgenic” activities of 19-nortestosterone. J Steroid Biochem 17, 653–660 (1982).
Heemers, H. V. & Tindall, D. J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28, 778–808, https://doi.org/10.1210/er.2007-0019 (2007).
Benten, W. P. et al. Functional testosterone receptors in plasma membranes of T cells. FASEB J 13, 123–133 (1999).
Benten, W. P. et al. Testosterone signaling through internalizable surface receptors in androgen receptor-free macrophages. Mol Biol Cell 10, 3113–3123 (1999).
Nakhla, A. M., Leonard, J., Hryb, D. J. & Rosner, W. Sex hormone-binding globulin receptor signal transduction proceeds via a G protein. Steroids 64, 213–216 (1999).
Reckelhoff, J. F., Zhang, H. & Granger, J. P. Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension 31, 435–439 (1998).
Masubuchi, Y., Kumai, T., Uematsu, A., Komoriyama, K. & Hirai, M. Gonadectomy-induced reduction of blood pressure in adult spontaneously hypertensive rats. Acta Endocrinol (Copenh) 101, 154–160 (1982).
Chen, Y. F. & Meng, Q. C. Sexual dimorphism of blood pressure in spontaneously hypertensive rats is androgen dependent. Life Sci 48, 85–96 (1991).
Phillips, G. B. et al. Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J Hypertens 11, 699–702 (1993).
Jaffe, A. et al. Erectile dysfunction in hypertensive subjects. Assessment of potential determinants. Hypertension 28, 859–862 (1996).
Hughes, G. S., Mathur, R. S. & Margolius, H. S. Sex steroid hormones are altered in essential hypertension. J Hypertens 7, 181–187 (1989).
Zitzmann, M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 5, 673–681, https://doi.org/10.1038/nrendo.2009.212 (2009).
Liu, P. Y., Death, A. K. & Handelsman, D. J. Androgens and cardiovascular disease. Endocr Rev 24, 313–340, https://doi.org/10.1210/er.2003-0005 (2003).
Garcia-Cruz, E. et al. Hypertension, dyslipidemia and overweight are related to lower testosterone levels in a cohort of men undergoing prostate biopsy. Int J Impot Res 24, 110–113, https://doi.org/10.1038/ijir.2011.55 (2012).
Yassin, D. J., Doros, G., Hammerer, P. G. & Yassin, A. A. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 11, 1567–1576, https://doi.org/10.1111/jsm.12523 (2014).
Traish, A. M., Haider, A., Doros, G. & Saad, F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract 68, 314–329, https://doi.org/10.1111/ijcp.12319 (2014).
Bhattacharya, R. K. et al. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). BMC Endocr Disord 11, 18, https://doi.org/10.1186/1472-6823-11-18 (2011).
Haider, A., Saad, F., Doros, G. & Gooren, L. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. Obes Res Clin Pract 8, e339–349, https://doi.org/10.1016/j.orcp.2013.10.005 (2014).
Anaissie, J., Roberts, N. H., Wang, P. & Yafi, F. A. Testosterone Replacement Therapy and Components of the Metabolic Syndrome. Sex Med Rev 5, 200–210, https://doi.org/10.1016/j.sxmr.2017.01.003 (2017).
Miner, M., Barkin, J. & Rosenberg, M. T. Testosterone deficiency: myth, facts, and controversy. Can J Urol 21(Suppl 2), 39–54 (2014).
Vigen, R. et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310, 1829–1836, https://doi.org/10.1001/jama.2013.280386 (2013).
Finkle, W. D. et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 9, e85805, https://doi.org/10.1371/journal.pone.0085805 (2014).
Valente, M. A. et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J 35, 1284–1293, https://doi.org/10.1093/eurheartj/ehu065 (2014).
English, K. M., Steeds, R. P., Jones, T. H., Diver, M. J. & Channer, K. S. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 102, 1906–1911 (2000).
Acknowledgements
This work was supported by the Fonds de recherche du Québec – Santé (Ag-06) and the J.-Louis Lévesque Foundation to J.W. It was also financed in part by grants from the Canadian Institutes of Health Research to J.W. (MOP69089 and MOP 123389), H.L. (MOP97829), and J.L. (MOP123395), the Natural Sciences and Engineering Research Council of Canada (RGPIN-2017-04790) and the Juvenile Diabetes Research Foundation (17-2013-440) to J.W., and a grant from the National Sciences Foundation of China to Y.W. (#81700363).
Author information
Authors and Affiliations
Contributions
Y.W., W.S., H.L., J.L. and J.W. generated the concept and initiated this project. Y.W. and W.S. conducted experiments in the cellular level and molecular level. A.B. and J.L. performed patch clamping experiments. J.P. was responsible for animal husbandry. S.Q. performed castration. Y.W., W.S., H.L., J.L. and J.W. drafted the manuscript.
Corresponding authors
Ethics declarations
Competing Interests
The authors declare that they have no competing interests.
Additional information
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Wang, Y., Shi, W., Blanchette, A. et al. EPHB6 and testosterone in concert regulate epinephrine release by adrenal gland chromaffin cells. Sci Rep 8, 842 (2018). https://doi.org/10.1038/s41598-018-19215-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-018-19215-2
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.